In two consecutive prospective randomised trials cyclosporin A has been compared with conventional immunosuppressive therapy (azathioprine and steroids) and with cyclosporin combined with steroids. The present report is a 4 year review and includes 165 patients.
INTRODUCTION
Since October 1980, 165 patients have been entered into two consecutive prospective randomised trials of the imunosuppressive drug cyclosporin A and have been followed up for a minimum of six months and a maximum of 4.5 years. In the first study cyclosporin A is compared with a conventional immunosuppressive regime of azathioprine and steroids. In the second, cyclosporin A alone is compared with cyclosporin A plus steroids. These studies have been conducted in a single centre with a large experience (600 patients) of conventional immunosuppressive therapy following cadaver renal transplantation.
PATIENTS AND METHODS
Only non-diabetic recipients of first and second cadaver renal grafts were considered. Every patient had previously received at least one blood transfusion; grafts were allocated on the basis of the least number of HLA-AB and DR mismatches. All patients received 500 mg methylprednisolone intravenously intra-operatively. Urine output was monitored hourly for the first six hours postoperatively and if it equalled or exceeded 50 ml/hr the recipient was entered into the trial by drawing a card to determine immunosuppressive therapy. Thereafter it was given in divided doses totalling 17 mg/kg/day in milk. The dose was reduced by 2 mg/kg at 2 weeks and 4 weeks, and then reduced monthly down to 5 mg/kg. In the event of toxic sideeffects the dose was reduced by one-third. If toxicity continued or was intolerable the patients were switched to conventional therapy.
Group III Cyclosporin A plus steroids: This group received cyclosporin A as above; in addition they were given low dose soluble prednisolone 0.25 mg/kg (to a maximum dose of 15 mg daily). Acute rejection had to be distinguished from nephrotoxicity; this was most often accomplished by biopsy. Confirmed rejection was treated by daily injections of 1 g methylprednisolone for 3 days. It was a condition of the trial that only two rejection episodes should be treated in the cyclosporin A group and a maximum of 6 g steroid given. If graft function remained impaired or there was further deterioration the patients was switched to conventional therapy. There were no serious imbalances of selection in any of the treatment groups. Age and sex were similarly distributed. HLA-AB and DR mismatches were close to 1.5 in the conventional group and 1.8 in the cyclosporin treated groups. All patients who lost their grafts and returned to dialysis were followed up for 1 year and included in the mortality data.
RESULTS
For ease of presentation and because the results were exactly the same the two cohorts of patients treated with cyclosporin alone have been combined. Graft survival for the three treatment groups is shown in Table 1 . All patients who initially received cyclosporin are included in the graft survival analysis for the cyclosporin group, regardless of whether or not they were subsequently converted to conventional therapy ('intention to treat' principle). One year graft survival was 80.2 % (65 of 81 grafts) in the cyclosporin alone group; this did not change significantly when steroids were added with survival at 78.6% (22 of 28 grafts). Both groups did significantly better than the conventional group where graft survival was 66% (37 of 56). (Table 111 ). This was because cyclosporin toxicity was reduced; conversion for rejection remained the same. Overall only one of 29 grafts was lost following conversion for toxicity whereas 13 out of 20 were lost when conversion was due to rejection. In the cyclosporin alone group there were 3 deaths (Table IV) , only one of which was related to immunosuppression. There were two deaths in the cyclosporin plus steroids group, one of which was due to viraemia. The highest mortality was in the conventional therapy group (6 of 56). Four of these could be attributed to immunosuppression.
The commonest side-effects amongst the cyclosporin treated patients were hirsutism 44%, fine tremor 39%, gingival hypertrophy 28%, nephrotoxicity 25%, hyperaesthesia 1 1 % and hyperkalaemia 9%. Most of these side-effects were minor and all were dose-related. They disappeared rapidly when cyclosporin was withdrawn or its dose reduced sharply. Nephrotoxicity was the commonest reason for conversion to conventional therapy. In patients on conventional therapy the commonest side-effects related to steroid therapy: cushingoid 5 and it is known to disappear on withdrawal of the drug. In this study many people were treated for rejection and then converted to conventional therapy as a condition of the trial, only to discover in retrospect that nephrotoxicity had been the problem. This resulted in an unacceptably high rate of conversion, 51.8% to conventional therapy. Sixteen patients (20.15%) were converted for rejection and to avoid the consequences of over-immunosuppression reported by the Cambridge group.' Of these, 10 subsequently lost their grafts. Twenty-five patients (30.8%) were converted for toxicity without graft loss. These changes reflect inexperience in the use of cyclosporin and also the lack of a meaningful assay. There is now evidence that much lower doses of cyclosporin can be used in conjunction with careful whole blood monitoring of the drug. Under these conditions improved graft survival is maintained and toxicity minimised. Our approach was to try and exclude rejection by biopsy and then reduce the dose by one-third. If a satisfactory result was obtained the dose was further reduced until the side-effects disappeared (therapeutic titration). Graft survival results in the sub-group of patients converted to conventional therapy was 76.2 % ; this was still significantly better than the conventional group, and it is of particular interest that only one graft was lost when conversion was because of toxicity. Steroids were combined with cyclosporin to see if graft survival could be further improved and in particular to see if nephrotoxicity was reduced. Graft survival was not significantly different when cyclosporin was given with maintenance steroids (78.6 %) but the rate of conversion for toxicity was significantly reduced, 14.28% compared with 40.7 %. Conversion for rejection was the same in the two groups. This advantage for maintenance steroids has to be balanced against the increased rate of steroid side-effects for no improvement in graft survival. In these studies we have limited entry to recipients with primary renal failure which excluded diabetic subjects and only included grafts that exhibited prompt diuresis. This was done in order to minimise the variables. Clearly the steroidsparing aspect of cyclosporin therapy should have advantages in the treatment of diabetics. Very few exclusions were made on grounds of no primary diuresis. 74% of kidneys used in this study were machine-perfused and, contrary to the Canadian Multicentre Trial Report,6 this appears to have improved the rate of entry and in no way adversely affected the outcome. Cyclosporin A alone has now become our first choice immunosuppressive agent. We no longer convert for persistent rejection, preferring loss of the graft if necessary, and we are attempting to reduce toxicity by daily monitoring of whole blood trough levels of the drug.
